WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology or “ACT” (OTCBB: ACTC) announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek. The coverage highlights a recent paper in the journal Stem Cells co-authored by ACT lead by its Chief Scientific Officer, Dr. Robert Lanza MD, and its collaborators. The paper reports that iPS cells exhibit abnormal expansion and early cellular aging, raising important questions about the future prospects for iPS cell-based therapies and supporting the use of ACT’s embryo-safe single blastomere-derived human embryonic stem cell lines, which do not exhibit these problems.
